249 related articles for article (PubMed ID: 12956200)
1. The use of topical therapies to treat onychomycosis.
Gupta AK; Ryder JE; Baran R
Dermatol Clin; 2003 Jul; 21(3):481-9. PubMed ID: 12956200
[TBL] [Abstract][Full Text] [Related]
2. Ciclopirox nail lacquer: a brush with onychomycosis.
Gupta AK
Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
[TBL] [Abstract][Full Text] [Related]
3. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy.
Baran R; Kaoukhov A
J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):21-9. PubMed ID: 15649187
[TBL] [Abstract][Full Text] [Related]
4. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.
Sidou F; Soto P
Int J Tissue React; 2004; 26(1-2):17-24. PubMed ID: 15573688
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents.
Shimamura T; Kubota N; Nagasaka S; Suzuki T; Mukai H; Shibuya K
Antimicrob Agents Chemother; 2011 Jul; 55(7):3150-5. PubMed ID: 21555762
[TBL] [Abstract][Full Text] [Related]
6. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
Gupta AK; Fleckman P; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
Gupta AK
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
[TBL] [Abstract][Full Text] [Related]
9. Ciclopirox nail lacquer solution 8% in the 21st century.
Gupta AK; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S96-102. PubMed ID: 11051138
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
Schaller M; Sigurgeirsson B; Sarkany M
Mycoses; 2017 Dec; 60(12):800-807. PubMed ID: 28925059
[TBL] [Abstract][Full Text] [Related]
11. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.
Brenner MA; Harkless LB; Mendicino RW; Page JC
J Am Podiatr Med Assoc; 2007; 97(3):195-202. PubMed ID: 17507527
[TBL] [Abstract][Full Text] [Related]
12. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis.
Jaiswal A; Sharma RP; Garg AP
Indian J Dermatol Venereol Leprol; 2007; 73(6):393-6. PubMed ID: 18032857
[TBL] [Abstract][Full Text] [Related]
13. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
Shemer A; Nathansohn N; Trau H; Amichai B; Grunwald MH
J Dermatol; 2010 Feb; 37(2):137-9. PubMed ID: 20175847
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.
Seebacher C; Nietsch KH; Ulbricht HM
Cutis; 2001 Aug; 68(2 Suppl):17-22. PubMed ID: 11665724
[TBL] [Abstract][Full Text] [Related]
15. Treatment costs of three nail lacquers used in onychomycosis.
Marty JP; Lambert J; Jäckel A; Adjadj L
J Dermatolog Treat; 2005; 16(5-6):299-307. PubMed ID: 16428149
[TBL] [Abstract][Full Text] [Related]
16. [Therapy with ciclopirox lacquer of onychomycoses caused by molds].
Ulbricht H; Wörz K
Mycoses; 1994; 37 Suppl 1():97-100. PubMed ID: 7854374
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review.
Feng X; Xiong X; Ran Y
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28097731
[TBL] [Abstract][Full Text] [Related]
18. Ciclopirox nail lacquer topical solution 8%.
Gupta AK
Skin Therapy Lett; 2000; 6(1):1-5. PubMed ID: 11027420
[TBL] [Abstract][Full Text] [Related]
19. Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective.
Gupta AK; Schouten JR; Lynch LE
Skin Therapy Lett; 2005 Sep; 10(7):1-3. PubMed ID: 16292454
[TBL] [Abstract][Full Text] [Related]
20. Onychomycosis.
Welsh O; Vera-Cabrera L; Welsh E
Clin Dermatol; 2010 Mar; 28(2):151-9. PubMed ID: 20347657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
